Document is current
Any future updates will be listed below
-
Authors
Brickwedde, Marion https://orcid.org/0000-0002-3461-038X
Anders, Paul https://orcid.org/0000-0002-5872-9916
Kühn, Andrea A.
Lofredi, Roxanne
Holtkamp, Martin
Kaindl, Angela M.
Grent-‘t-Jong, Tineke
Krüger, Peter
Sander, Tilmann https://orcid.org/0000-0003-2984-5579
Uhlhaas, Peter J. https://orcid.org/0000-0002-0892-2224
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (460785001, 460785001, 460785001, 460785001)
- License Information
-
More Information
Article History
Received: 12 July 2023
Revised: 25 June 2024
Accepted: 1 August 2024
First Online: 24 August 2024
Competing interests
: PJU reports having received research funding from Lilly UK and Lundbeck. RL reports personal fees from Medtronic. Prof. Kühn reports personal fees from Medtronic, and Boston Scientific. MH reports personal fees from Angelini, Bial, Desitin, Eisai, Jazz Pharma, UCB, and UNEEG within the last 3 years, outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest.
